Curated news and analysis on clinical trials, drug approvals, and medical research.
A randomized trial found that remote telehealth genetic services increase uptake of genetic counseling and testing in adult survivors of childhood cancer. At six months, 43% of the telehealth group received services vs. 15% in usual care, with actionable results in 10% of those tested.
The FDA proposes to remove three GLP-1 drugs from the bulk compounding list as adverse events near 2,000 and Senator Tom Cotton demands a probe into Chinese APIs in compounded meds. Shortages have largely resolved, but safety and innovation concerns persist.
The FDA has agreed to review Moderna's mRNA flu vaccine after initially rejecting it, with a decision expected by August 2026. The reversal occurs amid a contraction in the vaccine sector, with funding drops and layoffs under the Trump administration.
Two new surveys reveal that 24% of U.S. workers stay in unwanted jobs for health insurance, while 19% of adults with tinnitus have cut hours or quit. Debt and chronic illness increase job lock risk; cognitive behavioral therapy shows promise for tinnitus-related work impact.
Italian police seized pure cocaine valued at $286 million hidden in a banana shipment from Ecuador at the port of Vado Ligure. The 1,700-pound bust follows a similar seizure earlier this month and underscores the persistent use of banana shipments for international cocaine trafficking.
The acute pain market reached $4.5B in 2025, with 98% of pain drugs generic. Voltage-gated sodium channel inhibitors like Journavx offer non-opioid relief, while 39% of the pipeline uses non-small-molecule modalities.
Federated learning models have been shown to outperform all alternatives in drug discovery, while the broader life sciences sector increasingly relies on high-performance computing and AI-ready data infrastructure. These trends are reshaping R&D, with new collaborative approaches and data center demands driving innovation.
The FDA has approved Tregzi, a donor-derived T-cell immunotherapy, to reduce the risk of chronic graft-versus-host disease following stem cell transplant in adults with high-risk blood cancers. In a pivotal trial, 78% of recipients were alive and free of severe chronic GVHD at one year versus 38.4% with standard transplant.
Forge Biologics has partnered with Restore Vision to manufacture RV-001, a gene therapy for retinitis pigmentosa in Phase 1/2 trials in Japan. Forge also announced seven presentations at the ASGCT 29th Annual Meeting, highlighting process innovation and late-phase manufacturing capabilities. The company's CTO further discussed industrial-scale AAV gene therapy on The Genetics Podcast.
BioNTech reported a Q1 2026 net loss of $622.3 million as revenue declined to $138.0 million and R&D spending rose to $651.6 million. The company expanded its oncology pipeline with five new pivotal trials for pumitamig and announced manufacturing site exits to save $584.9 million annually by 2029.
Novartis posted Q2 2026 earnings above expectations but a 50% drop in Entresto sales from U.S. generics hurt performance. The company highlighted new EU and Japan approvals for Rhapsido and Itvisma, and a manufacturing restructuring including a German plant closure and investment in radioligand production. A $1.8 billion peptide drug pact with Unnatural Products was also announced.
Two fast-track housing projects in Queenstown aim to address acute shortages: a 2,800-home lakeside suburb has been approved, while a gondola and 1,300-unit plan faces local backlash over infrastructure and consultation concerns.
New Mexico lawmakers have launched a bipartisan investigation into Jeffrey Epstein's Zorro Ranch, examining potential sex trafficking and official corruption. The commission has subpoena power and a $2 million budget, and survivors have indicated abuse occurred at the ranch.
UNM Comprehensive Cancer Center installs MRI-LINAC, enabling real-time tumor tracking and adaptive radiation therapy. The system has treated 10 patients and improves precision, reducing damage to healthy tissue.
A retrospective study found comparable corticosteroid-free remission with upadacitinib and risankizumab in anti-TNF-exposed Crohn’s patients. Upadacitinib showed higher endoscopic remission at week 52 but more adverse events. Both JAK and IL-23 inhibitors are shaping the growing IBD treatment market.
U.S. hospitals face a 461% increase in NDM-gene CRE infections, while European data show high antibiotic resistance in foodborne bacteria like Salmonella and Campylobacter, with ciprofloxacin no longer effective for Campylobacter.
Nuvation Bio reported updated Phase 2 data for safusidenib in IDH1-mutant glioma with a 52% ORR and 79% 36-month PFS rate. The company is expanding its clinical program with two new studies and expanding the SIGMA trial to a pivotal Phase 3, aiming to address broader patient populations.
A review highlights that stromal cell metabolism in the tumor microenvironment dominates immune suppression. Cancer-associated fibroblasts and adipocytes release metabolites that impair antitumor immunity while favoring tumor-promoting immune cells. Targeting these metabolic networks could restore immune function and boost immunotherapy efficacy.
Kura Oncology's ziftomenib shows 96% complete response in frontline AML and $5.8M in early commercial sales; updated FIT-001 trial data for kidney cancer to be presented at 2026 summit; analysts see significant upside with an average target of $32.45.
A study in JAMA Open finds that anti-kickback penalties paid by pharma companies amounted to just 2.2% of U.S. revenue from involved drugs. Pfizer recently disclosed $60,000 in lobbying on drug pricing and vaccine issues. Researchers say settlements act as a cost of doing business.
